PDF(Pubmed)
Abstract：
The use of ibrutinib, a Bruton tyrosine kinase inhibitor, has been associated with invasive fungal infections (IFIs). We describe a case of Apophysomyces infection associated with long-term use of ibrutinib for the treatment of chronic lymphocytic leukemia as well as perform a literature review of Mucormycosis infections in patients on ibrutinib. Our review found that the onset of IFI can occur within months to years of starting tyrosine kinase inhibitors. These reports provide a more complete picture of the risk of IFI while patients are on ibrutinib. Our case also demonstrates the utility of molecular techniques in the diagnosis of IFI, as the diagnosis was made using 28S rDNA/internal transcribed spacer PCR.
摘要：
伊布替尼的使用，布鲁顿酪氨酸激酶抑制剂，与侵袭性真菌感染（IFIs）有关。我们描述了一例与长期使用依鲁替尼治疗慢性淋巴细胞白血病相关的Apophysomyces感染病例，并对依鲁替尼治疗患者的毛霉菌病感染进行了文献综述。我们的综述发现，在开始使用酪氨酸激酶抑制剂的几个月到几年内，会发生有助于减轻人的感染。这些报告提供了更完整的图像，说明患者服用伊布替尼时的风险。我们的案例还证明了分子技术在诊断国际金融机构中的实用性，因为诊断是使用28SrDNA/内部转录间隔区PCR进行的。
